HealthEconomics.Com Founder and CEO Dr. Patti Peeples recently discussed with HealthCore-NERI CMO Dr. Joseph Singer the impact of pragmatic clinical trials on real-world evidence (RWE).
HealthCore-NERI works with a range of stakeholders to deliver RWE to support a number of health care decisions.
“Real-world evidence using pragmatic clinical trials (PCTs) is increasingly being used for decision-making by payers, life science companies, health systems, and practicing physicians,” Singer says. “There is a need for devices and interventions, both biopharmaceutical and surgical, in a value-based system to demonstrate the actual benefit and risks occurring in a real-world patient setting, as opposed to the tightly-controlled populations of a traditional RCT.”
Singer says bringing together efficacy garnered from RCTs and effectiveness from PCTs has the potential “personalize most appropriate placement of an intervention in the treatment plan of individuals by their treating physicians.”
“PCTs enable the health care industry to more nimbly and efficiently answer questions related to how a treatment option performs in a real-world setting, contributing important evidence to establish future clinical guidelines that are applicable to a broad array of patients,” Singer says.
To read the full discussion on tHEORetically Speaking, click here.
